Last reviewed · How we verify
ABT-700
At a glance
| Generic name | ABT-700 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (PHASE2)
- Lung-MAP S1400K: c-MET Positive (PHASE2)
- Study of ABT-700 in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-700 CI brief — competitive landscape report
- ABT-700 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI